H
Hideki Hanaoka
Researcher at Chiba University
Publications - 73
Citations - 1984
Hideki Hanaoka is an academic researcher from Chiba University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 55 publications receiving 1412 citations. Previous affiliations of Hideki Hanaoka include Life Technologies.
Papers
More filters
Journal ArticleDOI
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer
Shinichiro Motohashi,Aki Ishikawa,Eiichi Ishikawa,Mizuto Otsuji,Toshihiko Iizasa,Hideki Hanaoka,Naomi Shimizu,Shigetoshi Horiguchi,Yoshitaka Okamoto,Shin-ichiro Fujii,Masaru Taniguchi,Takehiko Fujisawa,Toshinori Nakayama +12 more
TL;DR: The clinical trial with activated Vα24 NKT cell administration was well tolerated and carried out safely with minor adverse events even in patients with advanced diseases.
Journal ArticleDOI
A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer
Shinichiro Motohashi,Kaoru Nagato,Naoki Kunii,Heizaburo Yamamoto,Kazuki Yamasaki,K Okita,Hideki Hanaoka,Naomi Shimizu,Makoto Suzuki,Ichiro Yoshino,Masaru Taniguchi,Takehiko Fujisawa,Toshinori Nakayama +12 more
TL;DR: The administration of α-galactosylceramide KRN7000-pulsed IL-2/GM-CSF-cultured PBMCs was well tolerated and was accompanied by the successful induction of NKT cell-dependent immune responses, and the increased IFN-γ-producing cells that result from αGalCer stimulation inPBMCs were significantly associated with prolonged MST.
Journal ArticleDOI
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
Kazuki Yamasaki,Shigetoshi Horiguchi,Motoyoshi Kurosaki,Naoki Kunii,Kaoru Nagato,Hideki Hanaoka,Naomi Shimizu,Naoyuki Ueno,Seiji Yamamoto,Masaru Taniguchi,Shinichiro Motohashi,Toshinori Nakayama,Yoshitaka Okamoto +12 more
TL;DR: The combination therapy induced NKT cell-specific immune responses in cancer tissues that were associated with beneficial clinical effects and five cases achieved objective tumor regression.
Journal ArticleDOI
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial
Hiromichi Hamada,Hiroyuki Suzuki,Yoshihiro Onouchi,Ryota Ebata,Masaru Terai,Shigeto Fuse,Yoshitomo Okajima,Shunji Kurotobi,Katsuki Hirai,Takashi Soga,Yukiko Ishiguchi,Yoshiaki Okuma,Nobuyuki Takada,Masaaki Yanai,Junichi Sato,Mami Nakayashiro,Mamoru Ayusawa,Eiichi Yamamoto,Yuichi Nomura,Yuya Hashimura,Kazunobu Ouchi,Hiroshi Masuda,Shinichi Takatsuki,Keiichi Hirono,Tadashi Ariga,Takashi Higaki,Akio Otsuki,Moe Terauchi,Reiko Aoyagi,Takatoshi Sato,Yasuhisa Fujii,Tadami Fujiwara,Hideki Hanaoka,Akira Hata,Takafumi Honda,Kumi Yasukawa,Nishihara Takahiro,Hideoki Yajima,Hideyasu Ooto,You Umeda,Takashi Takeuchi,Tomohiro Suenaga,Nobuyuki Kakimoto,Masahiro Kamada,Shinichi Suwabe,Yasushi Ueno,Natsuko Nishi,Yuuko Saito,Yutaka Kitani,Taisuke Nabeshima,Kiyotaka Takefuta,Takahiro Nakamura,Akiko Komori,Masataka Kato,Naoki Saito,Kentaro Okunushi,Hironobu Kobayashi,Takeshi Nakano,Kiminori Masuda,Hirotaka Minami,Takamichi Uchiyama,You Okizuka,Naoki Ohno,Satoko Ogita,Hiroshi Ono,Akira Ishiguro,Tsutomu Saji,Fukiko Ichida,Sayaka Ozawa,Atsuhito Takeda,Gaku Izumi,Michiko Hanawa +71 more
TL;DR: Combined primary therapy with IVIG and ciclosporin was safe and effective for favourable coronary artery outcomes in Kawasaki disease patients who were predicted to be unresponsive to IVIG.
Journal ArticleDOI
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer
TL;DR: Metformin inhibited disease relapse after MPA therapy, and the combination of metformin and MPA in EC treatment should be studied further.